Aortic insufficiency repair device and method
This application relates to methods, systems, and apparatus for replacing native heart valves with prosthetic heart valves and treating valvular insufficiency. In a representative embodiment, a support frame configured to be implanted in a heart valve comprises an annular main body formed by a plurality of angled struts, the main body including a plurality of peaks formed by the intersection of respective adjacent struts. The support frame further comprises one or more leaflet-engaging mechanisms configured to engage leaflets of the heart valve. The support frame can be radially expandable and collapsible.
Latest Edwards Lifesciences Corporation Patents:
This application is a divisional of U.S. patent application Ser. No. 14/549,431, filed Nov. 20, 2014 which claims priority to and the benefit of U.S. Provisional Patent Application No. 61/907,650, filed Nov. 22, 2013, all of which are incorporated herein by reference in their entirety.
FIELDThis application relates to methods, systems, and apparatus for safely replacing native heart valves with prosthetic heart valves.
BACKGROUNDProsthetic heart valves have been used for many years to treat cardiac valvular disorders. The native heart valves (such as the aortic, pulmonary, tricuspid and mitral valves) serve critical functions in assuring the forward flow of an adequate supply of blood through the cardiovascular system. These heart valves can be rendered less effective by congenital, inflammatory, or infectious conditions. Such conditions can eventually lead to serious cardiovascular compromise or death. For many years the definitive treatment for such disorders was the surgical repair or replacement of the valve during open heart surgery.
More recently a transvascular technique has been developed for introducing and implanting a prosthetic heart valve using a flexible catheter in a manner that is less invasive than open heart surgery. In this technique, a prosthetic valve is mounted in a crimped state on the end portion of a flexible catheter and advanced through a blood vessel of the patient until the valve reaches the implantation site. The valve at the catheter tip is then expanded to its functional size at the site of the defective native valve, such as by inflating a balloon on which the valve is mounted. Alternatively, the valve can have a resilient, self-expanding stent or frame that expands the valve to its functional size when it is advanced from a delivery sheath at the distal end of the catheter.
Balloon-expandable valves are commonly used for treating heart valve stenosis, a condition in which the leaflets of a valve (e.g., an aortic valve) become hardened with calcium. The hardened leaflets provide a good support structure on which the valve can be anchored within the valve annulus. Further, the catheter balloon can apply sufficient expanding force to anchor the frame of the prosthetic valve to the surrounding calcified tissue. There are several heart conditions, however, that do not involve hardened valve leaflets but which are still desirably treated by valve replacement. For example, aortic insufficiency (or aortic regurgitation) occurs when an aortic valve does not close properly, allowing blood to flow back into the left ventricle. One cause for aortic insufficiency is a dilated aortic annulus, which prevents the aortic valve from closing tightly. In such cases, the leaflets are usually too soft to provide sufficient support for a balloon-expandable prosthetic valve. Additionally, the diameter of the aortic annulus may continue to vary over time, making it dangerous to install a prosthetic valve that is not reliably secured in the valve annulus. Mitral insufficiency (or mitral regurgitation) involves these same conditions but affects the mitral valve.
Self-expanding prosthetic valves are sometimes used for replacing defective native valves with non-calcified leaflets. Self-expanding prosthetic valves, however, suffer from a number of significant drawbacks. For example, once a self-expanding prosthetic valve is placed within the patient's defective heart valve (e.g., the aorta or mitral valve), it continues to exert an outward force on the valve annulus. This continuous outward pressure can cause the valve annulus to dilate further, exacerbating the condition the valve was intended to treat. Additionally, when implanting a self-expanding valve, the outward biasing force of the valve's frame tends to cause the valve to be ejected very quickly from the distal end of a delivery sheath.
The size of the prosthetic valve to be implanted into a patient can also be problematic when treating aortic or mitral insufficiency. Specifically, the size of a prosthetic valve used to treat aortic or mitral insufficiency is typically larger than a prosthetic valve used to treat aortic or mitral stenosis. This larger valve size makes the delivery procedure much more difficult.
Additionally, many prosthetic heart valves are retained by a stent or frame (i.e., a “pinch”) placed in the aortic annulus prior to implantation of the valve, with the valve being configured to pinch the native valve leaflets against the frame. However, such frames typically require attachment to the delivery apparatus to hold the frame in place before and/or during implantation of the prosthetic heart valve. This requires that the frame delivery apparatus remain in the patient during implantation of the prosthetic heart valve, which can complicate implantation of the valve.
Accordingly, there exists a need for improved methods, systems, and apparatus for delivering expandable prosthetic heart valves (e.g., balloon-expandable prosthetic valves). Embodiments of the methods, systems, and apparatus desirably can be used to replace native heart valves that do not have calcified leaflets (e.g., aortic valves suffering from aortic insufficiency). Furthermore, embodiments of the methods, systems, and apparatus desirably enable precise and controlled delivery of the prosthetic valves.
SUMMARYAn aortic insufficiency repair device improves aortic valve function by reducing a diameter of the aortic valve annulus, either an actual diameter and/or effective diameter. Embodiments of the device comprise a percutaneous or minimally invasively implantable ring-shaped or annular support structure that is deployable and anchorable on the downstream side of the aortic valve. Some embodiments of the device clip onto the native leaflets of the aortic valve at or near the commissures, thereby reducing the effective diameter of the valve annulus. Some embodiments of the device are secured in an over-expanded state and reduce the actual diameter of the aortic valve when the device springs back towards its default size.
Also disclosed below are representative embodiments of methods, systems, and apparatus used to replace deficient native heart valves with prosthetic heart valves. Embodiments of the disclosed methods, systems, and apparatus can be used, for example, to replace an aortic valve suffering from aortic insufficiency or a mitral valve suffering from mitral insufficiency. These embodiments are not limiting, however, as the disclosed methods, systems, and apparatus can be more generally applied to replace any heart valve.
In another representative embodiment a support frame configured to be implanted in a heart valve comprises an annular main body formed by a plurality of angled struts, the main body including a plurality of peaks formed by the intersection of respective adjacent struts. The support frame further comprises one or more leaflet-engaging mechanisms located beneath respective peaks of the support frame. Each of the one or more leaflet-engaging mechanisms defines a leaflet-receiving space between two opposing surfaces for engaging portions of adjacent leaflets therebetween, wherein the leaflet-receiving space can be adjustable to facilitate placement of the portions of the adjacent leaflets within the leaflet-engaging mechanism. The support frame can be radially expandable and collapsible.
In particular embodiments, the one or more leaflet-engaging mechanisms can comprise one or more pairs of leaflet clipping arms located beneath respective peaks of the support frame, wherein each clipping arm comprises a fixed end portion and a free end portion, the free end portions of each pair being configured to engage portions of adjacent leaflets therebetween. In some embodiments, the fixed end portion of each leaflet clipping arm is connected to a respective strut at a location below a respective peak and the leaflet clipping arm extends from the fixed end portion to the free end portion in a direction toward the peak. In other embodiments, the fixed end portion of each leaflet clipping arm is connected to a respective strut at a location below a respective peak and the leaflet clipping arm extends from the fixed end portion to the free end portion in a direction away from the peak.
In some embodiments, the free end portions of each pair of leaflet clipping arms can be curved or bent away from each other.
In some embodiments, the one or more leaflet-engaging mechanisms can be movable between an open position and a closed position. In some embodiments, the support frame is configured such that when the support frame is partially deployed from a delivery catheter the one or more leaflet-engaging mechanisms are in the open position. In some embodiments, the support frame is configured such that when the support frame is fully deployed from the delivery catheter the one or more leaflet-engaging mechanisms move to the closed position.
In some embodiments, the support frame further comprises one or more leaflet-engaging subunits.
In some embodiments, the one or more leaflet-engaging mechanisms are configured to be positioned over one or more commissures formed by the leaflets of the heart valve. In some embodiments, the one or more leaflet-engaging mechanisms comprise three leaflet-engaging mechanisms configured to engage the commissures of the aortic valve.
In some embodiments, the support frame further comprises one or more retaining arms coupled to the one or more of the peaks, the one or more retaining arms being configured to engage a delivery device.
In some embodiments, the support frame is configured to reduce the orifice area of the heart valve after implantation.
In another representative embodiment, a method of treating valvular insufficiency comprises inserting a delivery catheter into the vasculature of a heart proximate a heart valve, the delivery catheter carrying a support frame in a radially collapsed state. The method can further comprise positioning the delivery catheter such that one or more leaflet-engaging mechanisms of the support frame are aligned with commissures of the heart valve. Each of the one or more leaflet-engaging mechanisms is located below a respective apex of the support frame and defines a leaflet-receiving space between two opposing surfaces, wherein the leaflet-receiving space is adjustable. The method further comprises at least partially deploying the support frame from the delivery catheter to allow the support frame to radially expand to at least a partially deployed state, and engaging one or more of the commissures of the heart valve with the one or more leaflet-engaging mechanisms.
In some embodiments, the act of at least partially deploying the support frame causes the one or more leaflet-engaging mechanisms to move to open position to increase the leaflet-receiving space.
In some embodiments, the method further comprises fully deploying the support frame from the delivery catheter such that the one or more leaflet-engaging mechanisms move from the open position to a closed position.
In some embodiments, engaging one or more of the commissures of the heart valve with the one or more leaflet-engaging mechanisms is effective to reduce the orifice area of the heart valve.
In some embodiments, the method further comprises releasing the support frame from the delivery catheter and allowing the leaflets to regulate the flow of blood through the heart valve.
In some embodiments, the method further comprises, after releasing the support frame from the delivery catheter and allowing the leaflets to regulate the flow of blood through the heart valve, deploying a prosthetic heart valve within the leaflets such that the leaflets are captured between the support frame and the prosthetic heart valve.
In some embodiments, the act of engaging comprises actuating one or more leaflet-engaging mechanisms from an open position to a closed position such that the leaflet-engaging mechanisms engage the commissures of the heart valve.
In another representative embodiment, a support frame configured to be implanted in a heart valve comprises an annular main body formed by a plurality of angled struts, the main body including a plurality of peaks formed by the intersection of respective adjacent struts. In lieu of or in addition to one or more leaflet-engaging mechanisms, the support frame can have one or more frame-retaining mechanisms configured to restrain movement of the support frame in the heart by engaging one or more portions of the aortic root and/or the aorta. The support frame can be radially expandable and collapsible.
The foregoing and other objects, features, and advantages of the invention will become more apparent from the following detailed description, which proceeds with reference to the accompanying figures.
General Considerations
Disclosed below are representative embodiments of a support structure (sometimes referred to as a “support stent,” “support frame,” “support band,” or “support loop”) that can be used to secure a prosthetic heart valve within a native heart valve or reduce the orifice area of a native heart valve. For illustrative purposes, embodiments of the support structure are described as being used to secure a transcatheter heart valve (“THV”) in the aortic valve or the mitral valve of a heart. It should be understood that the disclosed support structure and THV can be configured for use with any other heart valve as well. Also disclosed herein are exemplary methods and systems for deploying the support structure and corresponding THV. Although the exemplary methods and systems are mainly described in connection with replacing an aortic or mitral valve, it should be understood that the disclosed methods and systems can be adapted to deliver a support structure and THV to any heart valve. Further, as used herein, the term “coupled” encompasses mechanical as well as other practical ways of coupling or linking items together, and does not exclude the presence of intermediate elements between the coupled items.
For illustrative purposes, certain embodiments of the support structure are described as being used in connection with embodiments of the balloon-expandable THV described in U.S. Patent Application Publication Nos. 2007/0112422 (U.S. application Ser. No. 11/280,063) and 2010/0049313 (U.S. application Ser. No. 12/429,040), which is hereby expressly incorporated herein by reference. It should be understood, however, that this particular usage is for illustrative purposes only and should not be construed as limiting. Instead, embodiments of the disclosed support structure can be used to secure a wide variety of THVs delivered through a variety of mechanisms (e.g., self-expanding heart valves, other balloon-expanding heart valves, and the like). For instance, any of the embodiments described in U.S. Pat. No. 6,730,118 can be used with embodiments of the disclosed support structure. U.S. Pat. No. 6,730,118 is hereby expressly incorporated herein by reference.
The specification and claims sometimes refer to a first catheter being “advanced” relative to a second catheter. It should be noted that this language not only encompasses situations where the first catheter is physically moved by an operator relative to the second catheter but also encompasses situations where the second catheter is physically moved by the operator relative to the first catheter (e.g., the second catheter is withdrawn over the first catheter, thereby causing the first catheter to be advanced relative to the second catheter). Likewise, the specification and claims sometimes refer to a first catheter being “withdrawn” relative to a second catheter. It should be noted that this language not only encompasses situations where the first catheter is physically moved by an operator relative to the second catheter but also encompasses situations where the second catheter is physically moved by the operator relative to the first catheter (e.g., the second catheter is advanced over the first catheter, thereby causing the first catheter to be withdrawn relative to the second catheter).
The described methods, systems, and apparatus should not be construed as limiting in any way. Instead, the present disclosure is directed toward all novel and nonobvious features and aspects of the various disclosed embodiments, alone and in various combinations and sub-combinations with one another. The disclosed methods, systems, and apparatus are not limited to any specific aspect, feature, or combination thereof, nor do the disclosed methods, systems, and apparatus require that any one or more specific advantages be present or problems be solved.
Although the operations of some of the disclosed methods are described in a particular, sequential order for convenient presentation, it should be understood that this manner of description encompasses rearrangement, unless a particular ordering is required by specific language set forth below. For example, operations described sequentially may in some cases be rearranged or performed concurrently. Moreover, for the sake of simplicity, the attached figures may not show the various ways in which the disclosed methods, systems, and apparatus can be used in conjunction with other systems, methods, and apparatus.
Repairing Aortic Insufficiency
Embodiments of the support structures, stents, or frames disclosed herein are suitable for repairing aortic valve insufficiency or aortic valve regurgitation in which the native aortic valve leaflets no longer coapt properly or completely, allowing blood to leak or backflow through the aortic valve during diastole. Some of the support structures described below can repair or improve aortic insufficiency by reducing a diameter of the aortic valve annulus, either an actual diameter or an effective diameter. Some embodiments of the support structures clip together the native aortic valve leaflets at or near the commissures, thereby reducing the effective diameter of the annulus. Some embodiments pull the annulus of the valve radially inwards, thereby reducing the actual diameter by radially overexpanding the support structure, engaging the support structure with one or more structures of the aortic valve, for example, the native leaflets and/or valve annulus, and allowing the support structure to radially contract to the default size, thereby reducing the diameter of the valve annulus. Some embodiments do both.
In some cases, the support structure will by itself repair or ameliorate aortic insufficiency by itself. If the function of the valve deteriorates, for example, over the course of months or years, a THV is then deployed, using the support structure as a dock therefor, as described in detail below.
Exemplary Embodiments for Replacing Aortic Valves
In the illustrated embodiment, the projection of the support stent 10 onto an x-y plane has a generally annular or toroidal shape. The illustrated support stent 10 further defines a number of peaks and valleys (or crests and troughs) along its circumference. For example, the support stent 10 is sinusoidally shaped in the z direction. In other embodiments, the support stent 10 is shaped differently in the z direction (e.g., sawtooth-shaped, ringlet-shaped, square-wave shaped, or otherwise shaped to include peaks and valleys).
The illustrated support stent 10 includes three peaks 20, 22, 24 and three valleys 30, 32, 34. In the illustrated embodiment, the peaks 20, 22, 24 are positioned above the valleys 30, 32, 34 in the z direction. In some embodiments, the peaks have greater radii than the valleys 30, 32, 34, or vice versa. For instance, in some embodiments, the projection of the support stent 10 onto an x-y plane forms a closed shape having a variable radius (e.g., a starfish shape).
The size of the support stent 10 can vary from implementation to implementation. In particular embodiments, the support stent 10 is sized such that the support stent can be positioned within the aorta of a patient at a location adjacent to the aortic valve, thereby circumscribing the aortic valve. Furthermore, in order to frictionally secure a prosthetic heart valve in its interior, certain embodiments of the support stent 10 have a diameter that is equal to or smaller than the diameter of the prosthetic heart valve when fully expanded. In particular embodiments, for instance, the support stent can have an inner or outer diameter between 10 and 50 mm (e.g., between 17 and 28 mm) and a height between 5 and 35 mm (e.g., between 8 and 18 mm). Furthermore, the thickness of the annular body of the support stent 10 may vary from embodiment to embodiment, but in certain embodiments is between 0.3 and 1.2 mm.
It should be understood that the shape of the support stent or frame 10 can vary from implementation to implementation. For example, in some embodiments, the support stent is not sinusoidal or otherwise shaped in the z-plane. In other embodiments, the support stent is shaped as a cylindrical band or sleeve. In general, the support stent or frame can be any shape that defines an interior through which a THV can be inserted, thereby causing the native leaflets of the aortic valve (or other heart valve) to be pinched or securely held between the support stent and the THV. Furthermore, the support stent can have a more complex structure. For example, although the support stent illustrated in
Returning to
A proximal end (not shown) of the guide catheter 102 is connected to a handle of the delivery apparatus 100. During delivery of a support stent, the handle can be used by a clinician to advance and retract the delivery apparatus through the patient's vasculature. In a particular use, the delivery apparatus 100 is advanced through the aortic arch of a patient's heart in the retrograde direction after having been percutaneously inserted through the femoral artery. The guide catheter can be configured to be selectively steerable or bendable to facilitate advancement of the delivery system 100 through the patient's vasculature. An exemplary steerable guide catheter as can be used in embodiments of the disclosed technology is described in detail in U.S. Patent Application Publication No. 2007/0005131 (U.S. patent application Ser. No. 11/152,288), which is hereby expressly incorporated herein by reference.
The delivery apparatus 100 also includes a stent delivery catheter 108 positioned in the interior of the guide catheter 102. The stent delivery catheter 108 has an elongated shaft 110 and an outer fork 140 connected to a distal end portion of the shaft 110. The shaft 110 of the stent delivery catheter 108 can be configured to be moveable axially relative to the shaft 104 of the guide catheter 102. Furthermore, the shaft 110 of the stent delivery catheter 108 can be sized so that its exterior wall is adjacent to or in contact with the inner wall of the shaft 104 of the guide catheter 102.
The delivery apparatus 100 can also include an inner catheter 118 positioned in the interior of the stent deliver catheter 108. The inner catheter 118 can have an elongated shaft 120 and an inner fork 138 secured to the distal end portion of the shaft 120. The shaft 120 of the inner catheter 118 can be configured to be moveable axially relative to the shaft 104 of the guide catheter 102 and relative to the shaft 110 of the stent delivery catheter 108. Furthermore, the shaft 120 of the inner catheter 118 can be sized so that its exterior wall is adjacent to or in contact with the inner wall of the shaft 110 of the stent delivery catheter 108. A guide wire (not shown) can be inserted into the interior of the inner catheter 118. The guide wire can be used, for example, to help ensure proper advancement of the guide catheter 102 and its interior catheters through the vasculature of a patient.
As best shown in
Retracting the inner prong 141 proximally (in the direction of arrow 152) to remove the prong from the aperture 26 allows the retaining arm 21 to be removed from the aperture 155, effectively releasing the retaining arm from the retaining mechanism. For instance, the outer prong 145 and the retaining arm 21 can be formed such that when the inner prong 141 is withdrawn from the aperture 26, the outer prong 145 flexes radially inward (downward in
As best shown in the exploded view in
The head portion 148 of the outer fork can be secured to a distal end portion of the shaft 110 of the stent delivery catheter 108 in a similar manner. As shown in
In
In particular embodiments, the support stent 10 is shaped so that the THV can be positioned in the interior of the support stent along with the native leaflets of the aortic valve. More specifically, the support stent 10 can be shaped such that the native leaflets become trapped or pinched between the support stent 10 and the exterior of the THV when the THV is installed. For instance, the diameter of the support stent 10 can be equal to or smaller than the maximum diameter of the THV when fully expanded, thus causing the THV to be frictionally fit to the leaflets of the aortic valve and the support stent 10. This friction fit creates a solid foundation for the THV that is independent of the state or condition of the leaflets in the aortic valve. For example, THVs are most commonly used for treating aortic stenosis, a condition in which the leaflets of the aortic valve become hardened with calcium. The hardened leaflets typically provide a good support structure for anchoring the THV within the aortic annulus. Other conditions may exist, however, in which it is desirable to implant a THV into the aortic valve and which do not result in a hardening of the leaflets of the aortic valve. For instance, the support stent 10 can be used as a foundation for a THV when treating patients with aortic insufficiency. Aortic insufficiency results when the aortic annulus dilates such that the aortic valve does not close tightly. With this condition, the aortic annulus is larger than normal and would otherwise require a large THV. Using a support stent or frame (such as the support stent or frame 10), however, a smaller THV can be used, thereby making the THV delivery process easier and safer. Furthermore, the use of a support stent protects against displacement of the THV if there is any further dilation of the aortic valve.
A support stent can be used to secure a THV in any situation in which the aorta or aortic valve may not be in condition to help support the THV and is not limited to cases of aortic insufficiency. For example, a support stent 10 can be used in cases in which the aortic annulus is too dilated or in which the leaflets of the aorta are too weak or soft. The support stent can be used to create an anchor for the THV, for instance, in cases in which the native leaflet tissue is too soft because of excess collagen in the aorta.
Also seen in
In
Again, the precise positioning of the THV 250 may be accomplished by locating radiopaque markers on its distal and proximal ends. In some embodiments, the clinician can adjust the position of the valve 250 by actuating a steering or deflecting mechanism within the balloon catheter 230. Furthermore, the rotational orientation of the valve 250 can be adjusted relative to the cusps and commissures of the native aortic valve by twisting the balloon catheter 230 from its proximal end and observing specific markers on the valve (or balloon catheter) under fluoroscopy. One of the coronary ostia 280 opening into one of the sinuses of the ascending aorta is also shown in
It should be noted that the valve 250 can take a variety of different forms and may comprise an expandable stent portion that supports a valve structure. The stent portion desirably has sufficient radial strength to hold the valve at the treatment site and to securely engage the support stent 10. Additional details regarding balloon expandable valve embodiments that can be used in connection with the disclosed technology are described in U.S. Pat. Nos. 6,730,118 and 6,893,460, both of which are hereby expressly incorporated herein by reference.
Once the valve 250 is properly implanted, as seen in
The support stent 310 includes a generally cylindrical main body portion 320 and a rim portion 330. The support stent 310 can be a mesh structure, which can be formed, for example, from multiple elements in which approximately half of the elements are angled in a first direction and approximately half of the elements are angled in a second direction, thereby creating a criss-cross or diamond-shaped pattern. In the illustrated embodiment, the rim portion 330 has a greater diameter than the main body portion 320 and is formed as an extension at a bottom region of the main body portion that is folded outwardly from the main body portion and back toward a top region of the main body portion. The rim portion 330 thus forms a U-shaped rim or lip around the bottom region of the support stent 310. In general, the rim portion 330 is designed to have a diameter that is slightly larger than the walls of the aortic arch that surround the aortic valve. Thus, when the support stent 310 is delivered to the aortic valve and deployed at the aorta, the rim portion 330 expands to engage the surrounding aorta wall and frictionally secures the support stent 310. At the same time, the main body portion 320 defines an interior into which an expandable THV can be expanded and which further engages the native leaflets of the aortic valve. Thus, the main body portion 320 operates in the same manner as the support stent 10 described above and illustrated in
As best seen in
More specifically,
The support stent 310 can be positioned adjacent to the aortic valve 304 so that the rim portion 330 of the support stent engages the walls surrounding the aortic valve 304 and exerts an outward force against those walls, thereby securing the support stent 310 within the aorta. This positioning can be achieved, for example, by advancing the guide catheter 352 to a position directly adjacent the aortic valve 304 while the stent delivery catheter 354 and the inner catheter 356 are undeployed and while the support stent 310 remains in its compressed state. The guide catheter 352 can then be retracted while the stent delivery catheter 354 and the inner catheter 356 are held in place, thereby allowing the support stent 310 to expand toward its natural shape. As with the delivery system 100 described above, the position of the guide catheter 352 and the support stent 310 relative to the aortic valve 304, as well as the position of other elements of the system, can be monitored using radiopaque markers and fluoroscopy, or using other imaging systems such as transesophageal echo, transthoracic echo, IVUS, or an injectable dye that is radiopaque.
Once the support stent 310 is positioned into the desired location adjacent the aortic valve 304, the prongs of the inner fork 362 can be disengaged from the corresponding apertures of the retaining arms of the support stent 310. For example, the inner catheter 356 can be retracted into the interior of the stent delivery catheter 354, thereby releasing the support stent 310 from the outer fork 360 and the inner fork 362. The delivery system 350 can then be retracted from the aorta and removed from the patient's body.
With the support stent 310 secured to the aortic valve, a THV (such as any of the THVs discussed above) can be introduced. In contrast to the procedure illustrated in
Other methods of delivering a support stent and THV to the aortic valve or any other heart valve are also possible. For example, in certain embodiments, the support stent and the THV are delivered surgically to the desired heart valve (e.g., in an open-heart surgical procedure). Furthermore, in certain embodiments in which the support stent and THV are delivered surgically, non-compressible support stents and/or THVs are used.
Exemplary Embodiments for Treating Valve Insufficiency and Vessel Aneurysms
Aortic insufficiency (AI) can cause dilatation of the ascending aorta, causing aneurisms, as well as the aortic annulus. In order to prevent further dilatation, embodiments of the present invention provide for anchoring of a deflector that directs blood away from the aneurysm while at the same time treating the insufficient heart valve.
As shown in
The support structure 412 (stent or frame) includes, for example in
As noted above, it should be understood that the shape of the support stent or frame 410 can vary from implementation to implementation. For example, in some embodiments, the support stent is not sinusoidal or otherwise shaped in the z-plane. In other embodiments, the support stent is shaped as a cylindrical band or sleeve. In general, the support stent or frame can be any shape that defines an interior through which a THV can be inserted, thereby causing the native leaflets of the aortic valve (or other heart valve) to be pinched or securely held between the support stent and the THV. Furthermore, the support stent can have a more complex structure. For example, although the support stent illustrated in
The prosthetic valve 416 of the embodiment illustrated in
As shown in
In
Extending from the proximal end 430 in the distal direction is the body of the stent 414 that is formed by the interconnected struts 434 that define between them the cells 436. Preferably, the interconnected struts 434 are formed to promote flexibility and facilitate delivery through tortuous paths and extension over the aortic arch. For example, the strut pattern may be as shown (as a flattened portion of a laser-cut blank prior to expansion) in
An example of a flexible stent structure is the LIFESTENT manufactured by C.R. BARD, INC. which has a multi-dimensional helical structure that facilitates its use in tortuous paths of peripheral vasculature. Aspects of the LIFESTENT are described in U.S. Pat. No. 6,878,162 entitled “Helical Stent Having Improved Flexibility and Expandability” by Bales et al.
Such flexibility is advantageous for treatment of AI in that the stent 414, when extending along the aortic arch, has a tightly curved configuration with an external, long curvature 442 and an internal curvature 444. Along the external curvature 442 the cell sizes may be larger to allow for the longer path length. These cell sizes may be programmed into the stent by selective cutting and formation of the struts and cells and/or may appear due to the mechanical application of insertion and delivery into the aortic arch. Similarly, the internal curvature 444 may be programmed through selection of the strut structure and/or due to delivery.
In addition, the stent 414 may include structure that facilitates engagement, frictional or mechanical, of the surrounding lumen (e.g., the aorta) where the lumen is in adjacent contact with the stent. For instance, the struts 434 and cells 436 may have a pattern that facilitates frictional engagement, or may have barbs or hooks or micro-anchors or flared portions formed thereon to mechanically engage the lumen and facilitate the support structure 412's role of securing the medical device 410.
The distal end 432 of the stent 414 is positioned within the aortic arch distal the branch (e.g., brachiocephalic, common carotid and left subclavian) arteries extending off of the aorta. The distal end 432 may be a termination of the last row of the rings 438 or may include its own retaining arms 446 defining apertures 448. Use of the retaining arms 446 and apertures 448 enables use of the delivery apparatus 110 shown in
In another aspect, the cells 436 may include a relatively large cell structure positioned over and near the branch arteries. This facilitates perfusion of the branch arteries, such as by being located over the branch arteries at the aortic arch or closer to the valve for communication with the coronary arteries. The cell structure is relatively large in comparison to the remaining cells configured to support the lumen walls or abate blood flow against aneurysms or further vascular dilatation. In another aspect, the cell size may be selected to guard the branch arteries against embolic debris, so as to act as a partial deflector of such debris.
The length of the device 410, including the support structure 412 and stent 414, may be enough to extend from the native leaflets, through the sinus of valsalva, into the ascending aorta, over the aortic arch and potentially into the descending aorta. For example, the length of the device 410 may be 30 mm to 100 mm or longer. The stent 414 may also be tapered, small at the annulus to larger at the ascending aorta, columnar or have ends that are a larger diameter for sealing and anchoring, as shown in
Once this support structure 412 and stent 414 are deployed they act like a scaffold or anchoring device for other devices to be deployed inside of it, such as the prosthetic valve 416, which is delivered and anchored as described above, and one or more deflectors 418.
In
Advantageously, the stent 414 guards the aneurysm against the expansion pressure of the deflector 418 and the deflector can have a much smaller expanded diameter than the aneurysm and still is assured of a firm anchor.
Deployment of the medical device 410 of
Although the deflector 418 is shown in
Also, the foam may be configured, such as by being hydrophilic, to absorb and expand in blood and fill the space between the stent 414 and the lumen. A skin or impermeable layer can be also applied to the stent 414 or foam sleeve 456 so that the foam does not peel/break off and cause an embolism. The skin or impermeable layer inhibits seep of the passing blood through the foam to the aortic wall. For example, an inner surface of the foam sleeve 456 may have a relatively impermeable skin (such as a closed cell foam) to promote passage of blood therethrough while the outer surface is open celled and permeable for expansion.
The foam may also have coagulation properties that promote buildup of clots to help secure the medical device 410 and fill the aneurismal space. The foam may include, for example, a flexible ester polyurethane, reticulated open cell, felted foam with a pore size of 80-100 ppi, a density of 5.4-6.3 pcf. Also, thick woven sleeves may be used that expand in response to absorbing blood, such as a hydrophilic weave or foam.
During delivery, the foam sleeve 456 is crimped down with the stent 414 and then placed in the aorta of the patient. Upon expansion, the stent 414 expands and maintains its more rigid shape, whereas the foam can also expand and take up the current shape of the aorta. The foam advantageously fills the void between the stent 414 and the aneurysm wall, preventing blood (the continued pulse force) from reaching the aneurysm. The foam sleeve 456 creates a seal within the aorta forcing blood to be passed through the stent 414 diameter. It also has effective friction or outward forces on the aortic wall so as to restrict movement.
As shown in
In another aspect, the deflector 418 may include mechanical clot facilitators such as wires, coils or springs that fill the space between the stent 414 and the aneurysm walls to promote embolization therebetween.
The graft 418 with the seal 458 may be used in a during a “trans-aortic” THV implantation wherein the graft is first deployed in a percutaneous delivery. The THV is then delivered through the chest wall with a delivery tool (e.g., a catheter) and through a slit in the aorta (aortotomy) and finally through the slit or seal 458 in the graft. The slit then seals around the delivery tool to prevent blood loss. The THV is expanded into place within the support structure 412 or stent 414. The seal 458 closes when the delivery tool is removed, allowing the aorta to be sutured without blood escaping. The graft 418 could be left behind—or it could be retrieved after completion of the procedure. Such a seal 458 may be employed in a range of embodiments with the deflector 418, including the embodiments disclosed herein.
In another embodiment, two anchoring stents may be connected by an elastic tube (e.g., made out of silicone). One of the anchors is deployed in the STJ (right above the native valve) and the other anchor is deployed on the other end of the aneurysm somewhere in the ascending aorta prior to the branches. The elasticity of the tube would aid the heart's pumping action.
Preferably, each of the medical devices 410 described herein is capable of a large amount of compression. For example the device 410, including the embodiment of the stent 414 and its foam sleeve 456, can be compressed or crimped to a diameter that is 8 mm or less. Uncompressed, the diameter may be 50 mm to 90 mm.
A method of using the medical device 410 disclosed herein includes delivering the support structure 412 to a position on or adjacent to the surface of the outflow side of the native heart valve of the patient, wherein the support structure defines a support-structure interior. The expandable prosthetic heart valve 416 is delivered into the native heart valve and into the support-structure interior. The expandable prosthetic heart valve 416 is expanded while it is in the support-structure interior and while the support structure is at the position on or adjacent to the surface of the outflow side of the native heart valve. This causes one or more of the native heart valve leaflets to be frictionally secured between the support structure 412 and the expanded prosthetic heart valve 416.
The stent 414, which is coupled to the support structure 412 either by co-formation or later attachment, is extended into a vessel (such as the aorta) extending from the native heart valve. The deflector 418 is already present on the stent 414 and/or is delivered into and attached to the stent 414. Blood flow against the vessel is abated by the deflector 418.
The method also may include delivering the stent 414 (or portions thereof) to a position adjacent the support structure 412 and coupling it to the support structure prior to extending the stent into the vessel. Also, the deflector 418 may be delivered to a support position on the stent 414 and coupled to the stent in vivo. Further, in the case where the stent 414 has a plurality of portions, the portions could be individually delivered and coupled to each other in vivo. Preferably, the method includes avoiding arteries extending from the vessel when positioning the deflector.
Also, the method may include expanding the deflector 418 to fill at least a portion of the space between an external surface of the stent 414 and the vessel.
If the stent 500 alone does not sufficiently reduce regurgitation or if the native valve further deteriorates over time after implantation of the stent 500, a THV can be deployed within the native valve, using a stent 500 as dock as shown in
Referring to
Once the microanchors 508 are implanted in the tissue of the valve annulus, tension can be applied to the sutures 512 such that the microanchors 508 are drawn toward one another, thereby reducing the diameter of the valve annulus (
In other embodiments, the support stent 500 can be implanted in a procedure in which the microanchors 508 are deployed adjacent the commissures of the native valve with each microanchor 508 being provided with a suture 512 that can extend to a delivery apparatus and/or outside the body. When implanting at the native aortic valve, three microanchors 508 (each having a respective suture) can be implanted. The sutures 512 can be threaded through openings in the apices 504 of the support stent 500, which can then be advanced along the sutures until it is placed against the aortic surface of the native leaflets. A suture clip 514 can be advanced down the sutures 512 to tension the sutures and draw the surrounding tissue inwardly to reduce the diameter of the native annulus (as depicted in
In alternative embodiments, the support stent 500 can be made of a self-expanding material (e.g., Nitinol) and is delivered and deployed using an expansion mechanism (e.g., a balloon catheter). When the support stent 500 is adjacent the native valve, the expansion mechanism over expands the support stent (i.e., expands the support stent radially beyond its functional size) (such as by inflating the balloon of the balloon catheter) and places the support stent against the aortic surface of the native valve. The support stent 500 can have barbs or anchors 508 can that engage, penetrate and/or grab adjacent tissue as the support stent 500 is placed against the native tissue. In lieu of or in addition to barbs or anchors, the support stent 500 can be configured to clip onto commissures of the native valve when the commissures are placed in gaps 506. The expansion mechanism then releases the support stent 500 (such as by deflating the balloon), allowing the support stent to shrink/return to its natural or functional size, pulling the surrounding tissue inwardly to reduce the size of the native annulus.
Alternatively, the aortic annulus can be reduced in size by suturing the support stent 500 in its functional size to the aortic valve.
In particular embodiments, the support stent has a pair of leaflet-engaging members 604 for each commissure of the native valve where the support stent is to be implanted. Thus, as shown in
In some embodiments, the clipping members 904 can be separately formed from the support frame 900, and can be fabricated from metal wire having a diameter that is smaller than the diameter of the struts 902. For example, in some embodiments, the diameter of the clipping members 904 can be from about 0.010 inch to about 0.023 inch. Each leg portion 906 of the clipping members 904 can also have a length L of, for example, 5 mm or greater (
In the embodiment of
Referring to
In the embodiment shown, the support frame 1400 can comprise a pair of leaflet-engaging members 1404 located beneath each apex 1406 of the frame. This can make implantation of the support frame 1400 easier by reducing the amount by which the frame 1400 must be rotated in order to line up the pairs of leaflet-engaging members with the commissures of the native valve. Alternatively, the support frame 1400 can have a pair of leaflet-engaging members 1404 for each commissure of the native valve where the support frame is to be implanted. Thus, similar to the embodiment of
In another alternative embodiment of the support frame 1500, the struts 1502 can define a single gap 1506 in the leaflet-engaging portion 1505, as shown in
The intermediate portions 1610 can include connecting members 1616 coupled to the struts 1602 of the stent 1600. In the embodiment shown, the connecting members 1616 can be coupled to the struts on or adjacent to the apices 1618 of the struts 1602. However, the connecting members 1616 can be coupled to the struts 1602 at any suitable location along the length of the struts. The connecting members 1616 can act as fulcrums about which the clipping arms 1606 pivot when moving between the open and closed positions.
The leaflet-engaging portions 1612 can be configured to engage the native leaflets 1622 when the clipping arms 1606 are in the closed position, as shown in
The struts 1602 and the one or more leaflet-engaging mechanisms 1604 can be laser cut (or otherwise machined or formed) from a single piece of material (e.g., a tubular piece of metal) such that the leaflet-engaging mechanisms 1604 are integral to the support stent. In other embodiments, the leaflet-engaging mechanisms 1604 can be separately formed and welded or otherwise coupled to the struts 1602. In some embodiments, the leaflet-engaging mechanisms 1604 can be located on the interior of the stent annulus. Alternatively, the leaflet-engaging mechanisms 1604 can be located on the exterior of the stent annulus. [Advantages?]
After fabrication of the stent, the clipping arms 1606 can be arranged on respective sides of the struts 1602, with the connecting members coupled to the struts, as shown in
In some embodiments, the proximal end portion 1708 of the elongated member 1706 can be curved radially inward (i.e., curved in a direction toward the center of the valve annulus), as shown in
The leaflet-engaging mechanisms 1704 can be integrally formed (e.g., by laser cutting, machining, or forming) with the stent 1700 from a single piece of material (e.g., a piece of metal). Alternatively, the leaflet-engaging mechanisms 1704 can be separately formed and welded or otherwise coupled to the stent 1700. When the support frame 1700 is intended to be implanted at the aortic valve or the pulmonary valve, the support stent 1700 desirably has three, angularly spaced leaflet-engaging mechanisms 1704, with each mechanism being positioned at a commissure of the native valve when the support stent 1700 is implanted, as shown in
Prior to implantation, the elongated member 1706 can be shape set such that it is biased toward the closed position, as described above. The flexible prongs 141 of the delivery system 350 can be threaded through the apertures 1720 of the retaining arms 1716 and through the holes 1710 of the elongated member 1706 such that the elongated member is held in the open position, as shown in
The open and closed positions can correspond to a radially collapsed state and a radially expanded state of the frame 1800, respectively. For example, when the frame 1800 is in a radially collapsed state, such as when loaded or partially deployed from a delivery catheter, the struts 1802 can be circumferentially displaced toward one another, as shown in
In the illustrated embodiment, the intermediate portions 1910 of the leaflet-engaging members 1904 can comprise peaks 1918 located approximately equidistant between the first and second apices 1906a, 1906b. The peaks 1918, along with the relatively long length of the intermediate portions 1910, can provide the leaflet-engaging members 1904 with some resiliency or flexibility which, in concert with the curved contact area, can reduce the risk of damage to the leaflets. The free end portions 1912 of the leaflet-engaging members 1904 of each respective pair can define a leaflet-engaging region or gap 1914 dimensioned to engage and retain the leaflets (not shown) of a native heart valve. In the embodiment shown, the free end portions 1912 of the leaflet-engaging members 1904 can define a curved leaflet contact area 1920, which can reduce the risk of damage to the leaflets. In some embodiments, the leaflet contact areas 1920 can include surface treatment such as projections, cutouts, surface roughness, etc., to aid in retaining the leaflets between the leaflet-engaging members.
In the embodiment shown, the first apices 1906a can comprise retaining arms 1916. In this manner, as the stent is deployed from a delivery catheter 1922, the second apices 1906b can emerge from the delivery catheter 1922 first, while the retaining arms 1916 of the first apices 1906a remain within the lumen of the delivery catheter 1922, as shown in
The leaflet-engaging members 1904 can be integrally formed with the stent 1900, or can be separately formed and secured to the stent by, e.g., welding, brazing, adhesive, etc. In the embodiment shown, the fixed-end portions 1908 are integrally formed with the first apices 1906a, while the intermediate portions 1910 are welded to the radially outward-facing surfaces of the struts 1902 of the second apices 1906b. In alternative embodiments, the fixed-end portions 1908 and the intermediate portions 1910 can both be integrally formed with the respective first and second apices 1906a, 1906b, or the fixed end portions 1908 and the intermediate portions 1910 can be separately formed and secured to the respective apices 1906a, 1906b as described above.
Referring to the frame subunit 2002 shown fully in
The leaflet-clipping subunits 2010 can each have a peak 2030 and a valley 2032. The peaks 2030 can be formed by the respective proximal intersections of the third and fourth branches 2022, 2024, and the fifth and sixth branches 2026, 2028, respectively, of the branching member 2002. Similarly, the valleys 2032 can be formed by the respective distal intersections of the third and fourth branches 2022, 2024, and the fifth and sixth branches 2026, 2028, respectively. The respective peaks 2030 of the leaflet-clipping subunits 2010 can be angled away from one another such that the leaflet-clipping subunits 2010 are biased toward the closed position when the frame is in the fully expanded configuration. In this manner, the leaflet-clipping subunits 2010 can be configured to engage and retain native leaflets 2038 between the respective leaflet-clipping subunits 2010 when the frame 2000 is deployed in a native valve 2034, as shown in
The support frame 2000 can be configured such that when partially deployed from the end of a delivery catheter 2040 with the actuator portions 2006 of the respective frame subunits 2002 within the catheter and the leaflet-clipping subunits 2010 outside the catheter, radial compression of the actuator portions 2006 can actuate or lever the leaflet-clipping subunits 2010 into the open position, as shown in
The branching members 2004 of the support frame can be laser cut (or otherwise machined or formed) from a single piece of material (e.g., a tubular piece of metal) such that the frame subunits 2002 are integral to the support stent. In other embodiments, the various branches of the branching members 2004 can be separately formed and welded or otherwise coupled together to form the frame subunits 2002. In further alternative embodiments, respective frame subunits can be integrally formed and then joined together by, for example, welding, brazing, adhesives, etc.
Each of the first frame members 2104 can comprise first and second internal branches 2114, 2116, which can define the actuator portions 2108 of the respective frame subunits 2102, as further described below. Each of the second frame members 2106 can comprise first and second external branches 2118, 2120, which can define respective boundaries of the leaflet-engaging portions 2110. In the embodiment shown, the frame subunits 2102 can be bounded by respective second frame members 2106.
The actuator portion 2108 can comprise a peak 2122 and a valley 2124. The peak 2122 can be formed by the intersection of the first internal branch 2114 and the second internal branch 2116 of the first frame member 2104 at a proximal end of the first frame member 2104. The first and second internal branches 2114, 2116 of the first frame member 2104 can be symmetrically arcuate, and can intersect one another at an intersection 2126 located at a distal end of the actuator portion 2108, thereby defining the valley 2124 of the actuator portion 2108. In the embodiment shown, the intersection 2126 can act as a lever, causing the leaflet-clipping subunits 2112 to move to the open position when radial compression is applied to the first and second internal branches 2114, 2116 of the actuator portion 2106. In alternative embodiments, the first and second internal branches 2114, 2116 of the first frame member 2104 need not intersect.
Referring to the leaflet-engaging portion 2110, the first and second internal branches 2114, 2116 of the first frame member 2104 can continue to extend distally from the intersection 2126 to a distal end of the leaflet-engaging portion 2110 where they can intersect the first and second external branches 2118, 2120 of the second frame member 2106 to form valleys 2128 of the respective leaflet-clipping subunits 2110. The first internal branches 2114 and the second external branches 2120, and the second internal branches 2116 and the first external branches 2118, can be interconnected by respective interconnecting members 2130. The interconnecting members 2130 can define peaks 2132, which can be angled away from one another. In this manner, the interconnecting members 2130 can act as springs biasing the leaflet-clipping subunits 2112 toward the closed position when the stent 2100 is in the fully expanded configuration. In this manner, the leaflet-clipping subunits 2112 can be configured to engage and retain native valve leaflets between the respective leaflet-clipping subunits when the frame is deployed in a native valve.
The support frame 2100 can be configured such that when partially deployed from the end of a catheter with the actuator portions 2108 of the respective frame subunits 2102 within the catheter and the leaflet-clipping subunits 2112 outside the catheter, radial compression of the actuator portions 2108 can actuate or lever the leaflet-clipping subunits 2112 into the open position, similar to the embodiment of
The first and second frame members 2104, 2106 of the support frame 2100 can be laser cut (or otherwise machined or formed) from a single piece of material (e.g., a tubular piece of metal) such that the frame subunits 2102 are integral to the support stent. In other embodiments, the various branches of the first and second frame members 2104, 2106 can be separately formed and welded or otherwise coupled together to form the frame subunits 2102.
Each of the frame members 2204 can comprise first and second branches 2212, 2214, which can define the actuator portions 2206 of respective frame subunits 2202, as further described below. Each respective first branch 2212 can further divide into third and fourth branches 2216, 2218, which can define respective boundaries of the leaflet-clipping subunits 2210, 2211. Similarly, each respective second branch 2214 can further divide into fifth and sixth branches 2220, 2222.
Referring to the frame subunits 2202 generally, the actuator portion 2206 can comprise a peak 2224 and two valleys 2226. The peak 2224 can be formed by the intersection of the first branch 2212 and the second branch 2214 of the frame member 2204 at a proximal end of the frame member 2204. The valleys 2226 can be defined by the fourth and fifth branches 2218, 2220, and an interconnecting member 2228, which can extend between the fourth and fifth branches 2218, 2220. In the embodiment shown, the second branch 2214 can have an arcuate portion 2232 extending laterally with respect to a longitudinal axis of the support frame 2200. In this manner, radial compression of the actuator portion 2206, and particularly of the second branch 2214, can cause the leaflet-clipping subunits 2210, 2211 to move to the open position.
Referring to the leaflet-engaging portion 2208, the third and fourth branches 2216, 2218 of the frame member 2204 can extend distally from the first branch 2212 to a distal end of the leaflet-engaging portion 2208 where they can intersect the sixth and fifth branches 2222, 2220, respectively. In this manner, the third and sixth branches 2216, 2222 of the frame member 2204 can define a valley 2235 of the leaflet-clipping subunit 2210, and the fourth and fifth branches 2218, 2220 can define a valley 2234 of the leaflet-clipping subunit 2211. The sixth branch 2222 and the third branch 2216 can also be interconnected by an interconnecting member 2229, similar to the interconnecting member 2228. The interconnecting members 2228, 2229 can comprise central peaks 2230, 2231, respectively, and can be angled away from one another. In this manner, the interconnecting members 2228, 2229 can act as springs, biasing the leaflet-clipping subunits 2210, 2211 toward the closed position when the stent 2200 is in the fully expanded configuration. In this manner, the leaflet-clipping subunits 2210, 2211 can be configured to engage and retain the native leaflets of a heart valve between the respective leaflet-clipping subunits when the frame is deployed in a native valve.
The support frame 2200 can be configured such that when partially deployed from the end of a catheter with the actuator portions 2206 of the respective frame subunits 2202 within the catheter and the leaflet-clipping subunits 2210, 2211 outside the catheter, radial compression of the actuator portions 2206 can actuate or lever the leaflet-clipping subunits 2210, 2211 into the open position, similar to the embodiment of
Referring to the frame subunits 2302 generally, the actuator portion 2306 can comprise a peak 2314 and a valley 2316. The peak 2314 can be formed by the intersection of a first branch 2318 and a second branch 2320 of the branching member 2004 at a proximal end of the actuator portion 2306. The first and second branches 2318, 2320 of the branching member 2304 can be angular, and can further branch into third and fourth branches 2322, 2324, and fifth and sixth branches 2326, 2328, respectively. In the embodiment shown, the third, fourth, fifth, and sixth branches 2322, 2324, 2326, 2328 are thicker than the first and second branches 2318, 2320 from which they originate. In this manner, the first and second branches 2318, 2320 can be configured to deform to a greater degree than the leaflet-clipping subunits 2310 when the when the support frame is in the open configuration. However, in alternative embodiments, all branches of the branching member 2304 can have the same thickness.
The valley 2316 can be defined by the convergence of the fourth and fifth branches 2324, 2326 of the branching member 2304 near a proximal end of the leaflet-engaging portion 2308, where the fourth and fifth branches 2324, 2326 can be interconnected by a spring member 2334. In the embodiment shown, the fourth and fifth branches 2324, 2326 converge, but do not intersect to form a single integral member. However, in alternative embodiments, the fourth and fifth branches 2324, 2326 can intersect to form an integral member, as desired. In the embodiment shown, the peak 2314 can further comprise a retaining arm 2311.
The leaflet-clipping subunits 2310 can each have a peak 2330 and a valley 2332. The peaks 2330 can be formed by the respective proximal intersections of the third and fourth branches 2322, 2324, and the fifth and sixth branches 2326, 2328, respectively, of the branching member 2302. Similarly, the valleys 2332 can be formed by the respective distal intersections of the third and fourth branches 2322, 2324, and the fifth and sixth branches 2326, 2328, respectively. The respective peaks 2330 of the leaflet-clipping subunits 2310 can be angled away from one another such that the leaflet-clipping subunits are biased toward the closed position when the frame is in the fully expanded configuration. In this manner, the leaflet-clipping subunits 2310 can be configured to engage and retain the native leaflets between the respective leaflet-clipping subunits 2310 when the frame 2300 is deployed in a native valve. As noted above, the fourth and fifth branches 2324, 2326 can also be interconnected by a spring member 2334, which can aid in biasing the leaflet-clipping subunits 2310 toward the closed position.
The support frame 2300 can be configured such that when partially deployed from the end of a catheter with the actuator portions 2306 of the respective frame subunits 2302 within the catheter and the leaflet-clipping subunits 2310 outside the catheter, radial compression of the actuator portions 2306 can actuate or lever the leaflet-clipping subunits 2310 into the open position (
The branching members 2304 of the support frame can be laser cut (or otherwise machined or formed) from a single piece of material (e.g., a tubular piece of metal) such that the frame subunits 2302 are integral to the support stent. In other embodiments, the various branches of the branching members 2304 can be separately formed and welded or otherwise coupled together to form the frame subunits 2302. In further alternative embodiments, respective frame subunits can be integrally formed and then joined together by, for example, welding, brazing, adhesives, etc.
For example, in the embodiment shown in
In an alternative embodiment shown in
Referring to
In some embodiments, the leaflet clips 2508 can be configured to match the geometric profile of the struts 2502 of the support frame 2500 such that the potential for the leaflet clips 2508 to interfere with positioning of the stent is reduced. For example, the clipping arms 2510 can define an angle θ between the hairpin portion 2514 and the intermediate portion 2516. The angle θ can be configured such that the diverging portions of the clipping arms 2510 approximate the profile of the struts 2502 of the support frame 2500. Similarly, the end portions 2520 of the clipping arms 2510 can be oriented at an angle α with the diverging portions of the clipping arms 2510 of the intermediate portion 2516. The end portions 2520 of the clipping arms 2510 can also have a length L. The angle α and the length L of the end portions 2520 can be selected to reduce the tendency of the leaflet clips 2508 to interfere with placement of the stent 2500 during implantation, while allowing the end portions 2520 to engage and retain the native leaflets. In some embodiments, the angle θ can be from about 130 degrees to about 170 degrees. In some embodiments, the angle θ can be about 147 degrees. In some embodiments, the angle α can be from about 45 degrees to about 60 degrees.
In some embodiments, the clipping arms 2510 of the leaflet clips 2508 can have a rectangular cross-sectional shape. This can increase the torsional stiffness of the clipping arms 2510, reducing the tendency of the end portions 2520 to rotate inwardly or outwardly when the clipping arms are forced together by the annular constraint 2512. In alternative embodiments, the clipping arms 2510 can have a round cross-sectional shape, or any other suitable cross-sectional shape.
The annular constraints 2512 can be configured as, for example, tubular members, suture loops, or folding tabs. In the embodiment shown, the annular constraints 2512 are configured as suture loops encircling each respective apex 2506 to which a leaflet-engaging mechanism 2504 is mounted. The annular constraints 2506 can also be configured as one or more suture loops that encircle each strut 2502 below the apex 2506 to which a leaflet-engaging mechanism 2504 is mounted. The annular constraints 2512 can be integral to the support frame 2500, or can be separately attached.
The following description concerns various embodiments of support frames that are configured to be self-retaining in the native valve through application of pressure to various anatomical structures of the native valve, such as via one or more frame-retaining mechanisms configured to engage portions of the aortic root and/or the aorta. Any of the embodiments described herein having leaflet-engaging mechanisms can be provided with one or more frame-retaining mechanisms described in detail below, unless the context suggests otherwise. Similarly, any of the embodiments described herein having one or more frame-retaining mechanisms can be provided with one or more leaflet-engaging mechanisms, unless the context suggests otherwise.
The following embodiments can be used for treating valve insufficiency by, for example, reducing the valvular circumference or reducing the valvular orifice area. The following embodiments can also be used for supporting a transcatheter heart valve (THV), and can be used in combination with any of the support frames described herein. Referring to
The arcuate members 2706 can comprise metal or polymer strips or hoops. In the embodiment shown, the arcuate members 2706 can contact the walls of the aortic root 2708 from substantially the aortic valve 2710 to substantially the sinotubular junction 2712. In this manner, the arcuate members 2706 can retain the support frame 2700 in place after implantation. In alternative embodiments, the height of the arcuate members 2706 can be configured such that the arcuate members 2708 contact any suitable portion of the walls of the aortic root 2708.
In some embodiments, the vertical members 2806 can be shape set such that the they are biased against the walls of the ascending aorta 2812 when the support stent 2800 is expanded to its fully expanded configuration. Similarly, the one or more horizontal members 2810 can be shape set to have a radius larger than the radius of the ascending aorta 2812 such that the horizontal members 2810 are biased against the walls of the ascending aorta 2812 when the support stent is fully expanded. The vertical and horizontal members 2806, 2810 can thereby work in concert to retain the support frame 2800 in position after implantation. The vertical and horizontal members 2806, 2810 can be fabricated from suitable shape-memory metals or alloys, such as spring steel, cobalt-chromium alloy (Elgiloy®), or nitinol, or from various polymeric materials.
The number, size, and position of the vertical and horizontal members 2806, 2810 can vary from implementation to implementation. For example, as shown in
In further alternative embodiments, the horizontal members 2810 can extend around less than the entire circumference of the ascending aorta 2812, and can be vertically offset from one another, as shown in
In another alternative embodiment shown in
Referring now to
In the embodiment shown, the support frame 2900 can comprise two vertical members 2910 on the portion of the support frame located in the dorsal half of the aorta 2906, and two vertical members 2910 on the portion of the support frame located in the ventral half of the aorta 2906 (not shown). However, in alternative embodiments, the support frame 2900 can include any suitable number of vertical members 2910 located on any suitable portion of the support frame 2900. The vertical members 2910 can be integrally formed with the support frame 2900, or can be separately formed and secured to the support frame by, for example, welding, brazing, suture, adhesives, etc.
In the embodiment shown, the height H can be configured such that the proximal apices 3004 are located adjacent the sinotubular junction 3012 and the distal apices 3008 are located adjacent the aortic valve 3014. In this manner, the struts 3002 can operate as a frame-retaining mechanism by contacting and exerting force against the walls of the aortic root 3010 along substantially the entire length of the aortic root 3010 from adjacent the sinotubular junction 3014 to adjacent the aortic valve leaflets 3014. Alternatively, the height H can be configured such that the struts 3002 contact any suitable portion of the walls of the aortic root 3010. In further alternative embodiments, the proximal apices 3006 can be configured to contact the sinotubular junction 3012 and the distal apices 3008 can be configured to contact the aortic valve leaflets 3014.
The first and second annular frames 3404, 3408 can be interconnected by one or more frame-retaining mechanisms configured as interconnecting members 3420. The one or more interconnecting members 3420 can be coupled to proximal apices 3422 of the first annular frame 3404 and to distal apices 3424 of the second annular frame 3408, and can be spring-biased. In this manner, the interconnecting members 3420 can urge the first annular frame 3404 downwardly, thereby helping to retain the support frame 3400 in place after implantation. In the embodiment shown, the interconnecting members 3420 can be configured to deflect and contact the walls of the aortic root and/or the sinotubular junction 3418, further increasing the stability of the support frame 3400 after implantation. In some embodiments, the interconnecting members 3420 can be made from metal (e.g., nitinol) or suitable biocompatible polymers, and can be integrally formed with the first and second annular frames 3404, 3408. Alternatively, the interconnecting members 3420 and the first and second annular frames 3404, 3408 can be separately formed and secured together by, for example, welding, brazing, suture, adhesives, etc.
The first and second annular frames 3504, 3508 can be interconnected by a frame-retaining mechanism configured as a spring member 3520. The spring member 3520 can be coupled to a respective proximal apex 3522 of the first annular frame 3504 and to a respective distal apex 3524 of the second annular frame 3508, and can be helically coiled. In this manner, the spring member 3520 can urge the first annular frame 3504 downwardly, thereby helping to retain the support frame 3500 in place after implantation. In the embodiment shown, the spring member 3520 is coupled to a single proximal apex 3522 of the first annular frame 3504 and a single distal apex 3524 of the second annular frame 3508. Alternatively, the spring member 3520 can be coupled to multiple proximal apices 3522 and/or multiple distal apices 3524 of the first and second annular frames 3504, 3508, respectively. In further alternative embodiments, the support frame 3500 can comprise multiple spring members 3520. In some embodiments, the spring member 3520 can be made from metal (e.g., nitinol) or suitable biocompatible polymers, and can be integrally formed with the first and second annular frames 3504, 3508. Alternatively, the spring member 3520 and the first and second annular frames 3504, 3508 can be separately formed and secured together by, for example, welding, brazing, suture, adhesives, etc.
The first and second annular frames 3602, 3606 can be interconnected by one or more frame-retaining mechanisms configured as interconnecting members 3618. The one or more interconnecting members 3618 can be coupled to respective proximal apices 3620 of the first annular frame 3602 and to respective distal apices 3614 of the second annular frame 3606, and can be helically coiled. In this manner, the interconnecting members 3618 can urge the first annular frame 3602 downwardly, thereby helping to retain the support frame 3600 in place after implantation. In the embodiment shown, an interconnecting member 3618 interconnects each proximal apex 3620 of the first annular frame 3602 with each distal apex 3614 of the second annular frame 3606. Alternatively, interconnecting members 3618 can interconnect every other proximal apex 3620 of the first annular frame 3602 with every other distal apex 3614 of the second annular frame 3606. In further alternative embodiments, each proximal apex 3620 of the first annular frame 3602 can be interconnected with each distal apex 3614 of the second annular frame 3606 by pairs of interconnecting members 3618, as shown in
In the embodiment shown, the vertical members 3710 can be integral with the semi-annular member 3708, and can be shape set such that the semi-annular member 3708 has a diameter greater than the ascending aorta 3714. In this manner, the semi-annular member 3708 can be configured to exert radial force against the walls of the ascending aorta 3714 which, in combination with the two vertical members 3710, can restrain upward movement of the support frame 3700 in the aortic root 3712. For example, in the embodiment of
The vertical members 3710 and the semi-annular member 3708 can be made from metal (e.g., nitinol) or from suitable biocompatible polymers, and can be integrally formed with the support frame 3700. Alternatively, the vertical members 3710 and the semi-annular member 3708 can be separately formed and secured to the support frame 3700 by, for example, welding, brazing, suture, adhesives, etc.
Each retaining member 3806 can comprise a proximal portion 3810 and a distal portion 3812. The proximal portion 3810 can be formed by respective end portions 3814 of loop or wire 3808, which can extend proximally from respective apices 3804, before curving distally. In this manner, the proximal portion 3810 can define a leaflet-engaging region 3822 configured to receive the native leaflets 3820, and the respective end portions 3814 of the loops 3808 can extend over the native valve leaflets 3820 when the support frame is implanted (see, e.g.,
In some embodiments, the loop or wire 3808 can extend proximally from the apices 3804 of the support frame 3800 for a distance of from about 5 mm to about 10 mm before curving distally. In some embodiments, the distal portions 3812 of the retaining members 3806 can have a height of from about 12 mm to about 18 mm. In this manner, the height of the retaining members 3806 can be approximately equal to the height of the native valve leaflets 3820, which can reduce the likelihood of damage to the leaflets 3820 during and after implantation.
Referring to
As shown in
The support frame 3800 can be configured such that as the THV 3828 and the support frame 3800 are radially expanded by the balloon catheter 3830, the support frame 3800 exerts a constant or nearly constant radial force on the THV 3828. For example, as shown in the stress-strain plot of
In an alternative embodiment shown in
The delivery device 3914 can comprise a plurality of first and second actuator members 3922, 3924 configured to engage the first and second apices 3906, 3910 of the leaflet-engaging mechanisms 3908 and the actuator mechanisms 3912, respectively. The first actuator members 3922 can be configured to apply compressive axial force to the first apices 3906 of the leaflet-engaging mechanisms 3908 in the direction indicated by arrows 3928 (i.e., the first actuator members 3922 can be configured to push downwardly on the first apices 3906 of the leaflet-engaging mechanisms 3908). Meanwhile, the second actuator members 3924 can be configured to apply tensile force to the second apices 3910 of the actuator mechanisms 3912 in the direction indicated by arrows 3930 (i.e., the second actuator members 3924 can be configured to pull upwardly on the second apices 3910 of the actuator mechanisms 3912). In this manner, the combined action of the first and second actuator members 3922, 3924 can cause the second struts 3904 of the actuator mechanisms 3912 to be drawn together while the first struts 3902 of the respective leaflet-engaging mechanisms 3908 are drawn apart, thereby moving the leaflet-engaging mechanisms 3908 into the open position, as shown in
The leaflet-engaging portion 3920 of the leaflet-engaging mechanism 3908 can define a leaflet-engaging region 3940 between the respective first struts 3902 configured to receive the native leaflets 3944. In some embodiments, the leaflet-engaging region 3940 can extend between the respective spring members 3934 of the spring subunits 3932. In the embodiment shown, the opposing surfaces of the first struts 3902 of the leaflet-engaging portion 3920 can comprise barbs 3942 configured to engage and retain the native leaflets. In alternative embodiments, the opposing surfaces of the first struts 3902 of the leaflet-engaging portion 3920 can comprise any suitable surface treatment such as projections, cutouts, surface roughness, etc., as desired. In some embodiments, the first and second struts 3902, 3904 can be integrally formed with the support frame 3900. Alternatively, the first and second struts 3902, 3904 can be separately formed and secured together by, for example, welding, brazing, suture, adhesives, etc.
The inner members 4002 can be arranged to form an inner clover 4008 having three inner apices 4010 formed by the intersection of adjacent inner members 4002. The outer members 4004 can be arranged to form an outer clover 4012 that is concentrically located with the inner clover 4008 and has a diameter greater than the inner clover 4008. The inner apices 4010 of the inner clover 4008 can be coupled to the respective crowns 4006 near the center of the crowns 4006, while the outer members 4004 can be coupled to sides of the respective crowns 4006. In this manner, the inner and outer members 4002, 4004 can define gaps 4014 therebetween extending along each aspect of the support frame 4000.
In the embodiment shown, the inner and outer members 4002, 4004 can be generally parallel, with the inner members 4002 extending radially inward of the outer members 4004. In this manner, the gaps 4014 can be configured to receive the native leaflets 4016 of the aortic valve 4018 (shown in phantom), with the inner members 4002 situated along the ventricular surface of the leaflets 4016 and the outer members 4004 situated along the aortic surface of the leaflets 4016 (when implanted in the native aortic valve). In some embodiments, the inner and outer members 4002, 4004 can be shape set such that they are spring-biased toward one another. In this manner, the inner and outer members 4002, 4004 can pinch and retain the native leaflets 4016 when the leaflets are inserted therebetween, thereby remodeling the aortic valve 4018 by reducing the valve circumference and/or the valvular orifice area. The inner and outer members 4002, 4004 can be made from metal (e.g., nitinol) or from suitable biocompatible polymers, and can be integrally formed with the support frame 4000. Alternatively, the inner and outer members 4002, 4004 can be separately formed and secured to the support frame 4000 by, for example, welding, brazing, suture, adhesives, etc.
Referring to
When the outer members 4004 of the outer clover 4012 are properly located behind the native leaflets (i.e., on the aortic side of the leaflets) and the inner members 4002 of the inner clover 4008 are properly located on the ventricular side of the native leaflets, the outer sheath 4024 can be fully retracted. The inner and outer clovers 4008, 4012 can then return to their respective natural diameters, engaging the native leaflets between the inner and outer clovers 4008, 4012 and drawing the native leaflets together, thereby reducing the circumference of the aortic valve and/or reducing the orifice area of the aortic valve.
In an alternative embodiment shown in
The clipping members 4108 can be located at the commissures 4118 of the aortic valve 4116 such that when the clipping members 4108 are moved from the unclamped to the clamped position, the native leaflets 4120 can be pinched against the underlying struts 4102 of the clover 4104. In some embodiments, the clover 4104 can be configured to have a diameter less than the natural diameter of the aortic valve 4116. In this manner, when the native leaflets 4120 are clipped against the clover 4104 by the clipping members 4108, the support frame 4100 can remodel the aortic valve 4116 by drawing the native valve leaflets 4120 together. This can reduce the circumference of the aortic valve 4116 and reduce the area of the valve orifice, thereby reducing regurgitation.
The support frame 4100 can be loaded onto the delivery device 4114 with the coupling members 4122 of the clipping members 4108 engaged with spherical end portions 4124 of the elongated members 4112. Initially, the clipping members 4108 can be located above the clover 4104 so as not to interfere with the placement of the clover 4104. The delivery device 4124 can be advanced through a surgical opening in the left ventricle and into the aorta, where the clover 4104 can be positioned such that the apices 4106 are located between the leaflets 4120 at the commissures 4118 of the aortic valve 4116. When the clover 4104 is properly located, the elongated members 4112 can be retracted, thereby moving the clipping members 4108 from the unclamped to the clamped position. This, in turn, can cause the leaflets 4120 to be pinched between the clipping members 4108 and the struts 4102 of the clover 4104. The coupling members 4122 can then be disengaged from the spherical end portions 4124 of the elongated members 4112, and the delivery device 4114 can be retracted.
In view of the many possible embodiments to which the principles of the disclosed invention may be applied, it should be recognized that the illustrated embodiments are only preferred examples of the invention and should not be taken as limiting the scope of the invention. Rather, the scope of the invention is defined by the following claims. We therefore claim as our invention all that comes within the scope and spirit of these claims.
Claims
1. A support frame configured to be implanted in a native heart valve, the support frame comprising:
- an inflow end and an outflow end;
- a radially expandable and collapsible annular main body including a plurality of angled struts and including a plurality of apices formed by the intersection of respective adjacent struts; and
- one or more pairs of clipping arms, each of the one or more pairs of clipping arms being located between two of the respective adjacent struts defining an apex of the main body, each of the clipping arms comprising a fixed end portion and a free end portion, the free end portion being offset from the apex in a direction toward the inflow end, the clipping arms defining a leaflet-receiving space between two opposing surfaces of the clipping arms for engaging portions of adjacent native leaflets of the native heart valve therebetween;
- wherein the clipping arms are disposed within an outer diameter of the support frame defined by the plurality of angled struts.
2. The support frame of claim 1, wherein the fixed end portion of each clipping arm of the one or more pairs of clipping arms is coupled to one of the respective adjacent struts, and the clipping arms extend in a direction toward the apex at the outflow end of the support frame.
3. The support frame of claim 1, wherein the fixed end portion of each of the clipping arms is coupled to one of the respective adjacent struts and the clipping arms extend in a direction toward the inflow end of the support frame.
4. The support frame of claim 1, wherein each clipping arm of the one or more pairs of clipping arms is curved such that the free end portion of each of the clipping arms is angled away from the other.
5. The support frame of claim 1, wherein the one or more pairs of clipping arms are movable between an open position and a closed position to adjust the leaflet-receiving space.
6. The support frame of claim 1, wherein the one or more pairs of clipping arms are configured to be positioned over one or more commissures formed by the native leaflets of the heart valve.
7. The support frame of claim 1, wherein the support frame comprises three pairs of clipping arms configured to engage commissures of the native heart valve.
8. The support frame of claim 1, wherein the support frame comprises one or more retaining arms coupled to respective of the apices, the one or more retaining arms being configured to engage a delivery device.
9. The support frame of claim 1, wherein the support frame is configured to reduce the orifice area of the heart valve after implantation.
10. The support frame of claim 1, wherein the main body is configured to receive and securely hold a separately deployable prosthetic heart valve when the main body is in a radially expanded state, the prosthetic heart valve including a frame and a leaflet structure situated within the frame.
11. The support frame of claim 1, wherein the free end portions of the clipping arms are located beneath the apex of the frame.
12. A support frame configured to be implanted in a native heart valve, the support frame comprising:
- an inflow end and an outflow end;
- a radially expandable and collapsible annular main body including a plurality of angled struts and including a plurality of apices formed by the intersection of respective adjacent struts; and
- one or more pairs of clipping arms, each of the one or more pairs of clipping arms being located between two of the respective adjacent struts defining an apex of the main body, each of the clipping arms comprising a fixed end portion and a free end portion, the free end portion being offset from the apex in a direction toward the inflow end, the clipping arms defining a leaflet-receiving space between two opposing surfaces of the clipping arms for engaging portions of adjacent native leaflets of the native heart valve therebetween;
- wherein the one or more pairs of clipping arms are movable between an open position and a closed position to adjust the leaflet-receiving space; and
- wherein when the support frame is partially deployed from a delivery catheter the one or more pairs of clipping arms are in the open position.
13. The support frame of claim 12, configured such that when the support frame is fully deployed from the delivery catheter the one or more pairs of clipping arms move to the closed position.
14. A support frame configured to be implanted in a native heart valve, the support frame comprising:
- an inflow end and an outflow end;
- a radially expandable and collapsible annular main body including a plurality of angled struts and including a plurality of apices formed by the intersection of respective adjacent struts; and
- one or more pairs of clipping arms, each of the one or more pairs of clipping arms being located between two of the respective adjacent struts defining an apex of the main body, each of the clipping arms comprising a fixed end portion and a free end portion, the free end portion being offset from the apex in a direction toward the inflow end, the clipping arms defining a leaflet-receiving space between two opposing surfaces of the clipping arms for engaging portions of adjacent native leaflets of the native heart valve therebetween;
- wherein the clipping arms of each pair of clipping arms overlap one another when the support frame is in an expanded configuration.
15. A support frame configured to be implanted in a native heart valve, the support frame comprising:
- an inflow end and an outflow end;
- a radially expandable and collapsible annular main body including a plurality of angled struts and including a plurality of apices formed by the intersection of respective adjacent struts; and
- one or more pairs of clipping arms, each of the one or more pairs of clipping arms being located between two of the respective adjacent struts defining an apex of the main body, each of the clipping arms comprising a fixed end portion and a free end portion, the free end portion being offset from the apex in a direction toward the inflow end, the clipping arms defining a leaflet-receiving space between two opposing surfaces of the clipping arms for engaging portions of adjacent native leaflets of the native heart valve therebetween;
- wherein at least one clipping arm of each of the one or more pairs of clipping arms comprises serrations.
16. A support frame configured to be implanted in a native heart valve, the support frame comprising:
- an inflow end and an outflow end;
- a radially expandable and collapsible annular main body including a plurality of angled struts and including a plurality of apices formed by the intersection of respective adjacent struts; and
- one or more pairs of clipping arms, each of the one or more pairs of clipping arms being located between two of the respective adjacent struts defining an apex of the main body, each of the clipping arms comprising a fixed end portion and a free end portion, the free end portion being offset from the apex in a direction toward the inflow end, the clipping arms defining a leaflet-receiving space between two opposing surfaces of the clipping arms for engaging portions of adjacent native leaflets of the native heart valve therebetween;
- wherein one clipping arm of each of the one or more pairs of clipping arms comprises a plurality of protrusions, and the other clipping arm comprises a plurality of corresponding recessed portions configured to receive the protrusions when the support frame is in an expanded configuration.
17. An assembly, comprising:
- a support frame configured to be implanted in a native heart valve, the support frame comprising: an inflow end and an outflow end; a radially expandable and collapsible annular main body including a plurality of angled struts and including a plurality of apices formed by the intersection of respective adjacent struts; and one or more pairs of clipping arms, each of the one or more pairs of clipping arms being located between two of the respective adjacent struts defining an apex of the main body, each of the clipping arms comprising a fixed end portion and a free end portion, the free end portions being offset from the apex in a direction toward the inflow end, the clipping arms defining a leaflet-receiving space between two opposing surfaces of the clipping arms for engaging portions of adjacent native leaflets of the native heart valve therebetween, the clipping arms being disposed within an outer diameter of the support frame defined by the plurality of angled struts; and
- a prosthetic heart valve including a frame and a leaflet structure, wherein the support frame and the prosthetic heart valve are configured to capture native leaflets of the native heart valve between the support frame and the prosthetic heart valve when the support frame and the prosthetic heart valve are deployed in the native heart valve.
18. The assembly of claim 17, wherein the fixed end portion of each clipping arm is coupled to one of the respective adjacent struts and extends in a direction toward the apex at the outflow end of the support frame.
19. The assembly of claim 17, wherein the fixed end portion of each clipping arm is coupled to one of the respective adjacent struts and the clipping arms extend in a direction toward the inflow end of the support frame.
20. The assembly of claim 17, wherein the support frame comprises three pairs of clipping arms configured to engage commissures of the native heart valve.
3409013 | November 1968 | Berry |
3472230 | October 1969 | Fogarty |
3548417 | December 1970 | Kisher |
3587115 | June 1971 | Shiley |
3657744 | April 1972 | Ersek |
3671979 | June 1972 | Moulopoulos |
3714671 | February 1973 | Edwards et al. |
3755823 | September 1973 | Hancock |
4035849 | July 19, 1977 | Angell et al. |
4056854 | November 8, 1977 | Boretos et al. |
4106129 | August 15, 1978 | Carpentier et al. |
4222126 | September 16, 1980 | Boretos et al. |
4265694 | May 5, 1981 | Boretos et al. |
4297749 | November 3, 1981 | Davis et al. |
4339831 | July 20, 1982 | Johnson |
4343048 | August 10, 1982 | Ross et al. |
4345340 | August 24, 1982 | Rosen |
4373216 | February 15, 1983 | Klawitter |
4406022 | September 27, 1983 | Roy |
4441216 | April 10, 1984 | Ionescu et al. |
4470157 | September 11, 1984 | Love |
4491986 | January 8, 1985 | Gabbay |
4501030 | February 26, 1985 | Lane |
4535483 | August 20, 1985 | Klawitter et al. |
4574803 | March 11, 1986 | Storz |
4592340 | June 3, 1986 | Boyles |
4605407 | August 12, 1986 | Black et al. |
4612011 | September 16, 1986 | Kautzky |
4643732 | February 17, 1987 | Pietsch et al. |
4655771 | April 7, 1987 | Wallsten |
4692164 | September 8, 1987 | Dzemeshkevich et al. |
4733665 | March 29, 1988 | Palmaz |
4759758 | July 26, 1988 | Gabbay |
4762128 | August 9, 1988 | Rosenbluth |
4777951 | October 18, 1988 | Cribier et al. |
4787899 | November 29, 1988 | Lazarus |
4787901 | November 29, 1988 | Baykut |
4796629 | January 10, 1989 | Grayzel |
4829990 | May 16, 1989 | Thuroff et al. |
4851001 | July 25, 1989 | Taheri |
4856516 | August 15, 1989 | Hillstead |
4878495 | November 7, 1989 | Grayzel |
4878906 | November 7, 1989 | Lindemann et al. |
4883458 | November 28, 1989 | Shiber |
4922905 | May 8, 1990 | Strecker |
4966604 | October 30, 1990 | Reiss |
4979939 | December 25, 1990 | Shiber |
4986830 | January 22, 1991 | Owens et al. |
4994077 | February 19, 1991 | Dobben |
5007896 | April 16, 1991 | Shiber |
5026366 | June 25, 1991 | Leckrone |
5032128 | July 16, 1991 | Alonso |
5037434 | August 6, 1991 | Lane |
5047041 | September 10, 1991 | Samuels |
5059177 | October 22, 1991 | Towne et al. |
5080668 | January 14, 1992 | Bolz et al. |
5085635 | February 4, 1992 | Cragg |
5089015 | February 18, 1992 | Ross |
5108370 | April 28, 1992 | Walinsky |
5141494 | August 25, 1992 | Danforth et al. |
5152771 | October 6, 1992 | Sabbaghian et al. |
5163953 | November 17, 1992 | Vince |
5167628 | December 1, 1992 | Boyles |
5192297 | March 9, 1993 | Hull |
5232446 | August 3, 1993 | Arney |
5266073 | November 30, 1993 | Wall |
5282847 | February 1, 1994 | Trescony et al. |
5295958 | March 22, 1994 | Shturman |
5332402 | July 26, 1994 | Teitelbaum |
5360444 | November 1, 1994 | Kusuhara |
5370685 | December 6, 1994 | Stevens |
5397351 | March 14, 1995 | Pavcnik et al. |
5411522 | May 2, 1995 | Trott |
5411552 | May 2, 1995 | Andersen et al. |
5443446 | August 22, 1995 | Shturman |
5480424 | January 2, 1996 | Cox |
5500014 | March 19, 1996 | Quijano et al. |
5545209 | August 13, 1996 | Roberts et al. |
5545214 | August 13, 1996 | Stevens |
5549665 | August 27, 1996 | Vesely et al. |
5554185 | September 10, 1996 | Block et al. |
5571175 | November 5, 1996 | Vanney et al. |
5591195 | January 7, 1997 | Taheri et al. |
5599305 | February 4, 1997 | Hermann et al. |
5607464 | March 4, 1997 | Trescony et al. |
5609626 | March 11, 1997 | Quijano et al. |
5639274 | June 17, 1997 | Fischell et al. |
5665115 | September 9, 1997 | Cragg |
5716417 | February 10, 1998 | Girard et al. |
5728068 | March 17, 1998 | Leone et al. |
5749890 | May 12, 1998 | Shaknovich |
5756476 | May 26, 1998 | Epstein et al. |
5769812 | June 23, 1998 | Stevens et al. |
5800508 | September 1, 1998 | Goicoechea et al. |
5840081 | November 24, 1998 | Andersen et al. |
5855597 | January 5, 1999 | Jayaraman |
5855601 | January 5, 1999 | Bessler et al. |
5855602 | January 5, 1999 | Angell |
5925063 | July 20, 1999 | Khosravi |
5957949 | September 28, 1999 | Leonhardt et al. |
5968068 | October 19, 1999 | Dehdashtian et al. |
5980570 | November 9, 1999 | Simpson |
5984959 | November 16, 1999 | Robertson et al. |
6027525 | February 22, 2000 | Suh et al. |
6042607 | March 28, 2000 | Williamson, IV et al. |
6132473 | October 17, 2000 | Williams et al. |
6168614 | January 2, 2001 | Andersen et al. |
6171335 | January 9, 2001 | Wheatley et al. |
6174327 | January 16, 2001 | Mertens et al. |
6210408 | April 3, 2001 | Chandrasekaran et al. |
6217585 | April 17, 2001 | Houser et al. |
6221091 | April 24, 2001 | Khosravi |
6231602 | May 15, 2001 | Carpentier et al. |
6245040 | June 12, 2001 | Inderbitzen et al. |
6245102 | June 12, 2001 | Jayaraman |
6299637 | October 9, 2001 | Shaolian et al. |
6302906 | October 16, 2001 | Goicoechea et al. |
6350277 | February 26, 2002 | Kocur |
6379372 | April 30, 2002 | Dehdashtian et al. |
6419695 | July 16, 2002 | Gabbay |
6425916 | July 30, 2002 | Garrison et al. |
6440164 | August 27, 2002 | DiMatteo et al. |
6454799 | September 24, 2002 | Schreck |
6458153 | October 1, 2002 | Bailey et al. |
6461382 | October 8, 2002 | Cao |
6468660 | October 22, 2002 | Ogle et al. |
6482228 | November 19, 2002 | Norred |
6488704 | December 3, 2002 | Connelly et al. |
6527979 | March 4, 2003 | Constantz et al. |
6569196 | May 27, 2003 | Vesely |
6582462 | June 24, 2003 | Andersen et al. |
6605112 | August 12, 2003 | Moll et al. |
6652578 | November 25, 2003 | Bailey et al. |
6730118 | May 4, 2004 | Spenser et al. |
6733525 | May 11, 2004 | Yang et al. |
6767362 | July 27, 2004 | Schreck |
6830584 | December 14, 2004 | Seguin |
6869444 | March 22, 2005 | Gabbay |
6878162 | April 12, 2005 | Bales et al. |
6893460 | May 17, 2005 | Spenser et al. |
6908481 | June 21, 2005 | Cribier |
7018406 | March 28, 2006 | Seguin et al. |
7018408 | March 28, 2006 | Bailey et al. |
7160322 | January 9, 2007 | Gabbay |
7276078 | October 2, 2007 | Spenser et al. |
7276084 | October 2, 2007 | Yang et al. |
7318278 | January 15, 2008 | Zhang et al. |
7374571 | May 20, 2008 | Pease et al. |
7381210 | June 3, 2008 | Zarbatany et al. |
7393360 | July 1, 2008 | Spenser et al. |
7462191 | December 9, 2008 | Spenser et al. |
7510575 | March 31, 2009 | Spenser et al. |
7527646 | May 5, 2009 | Randert et al. |
7563280 | July 21, 2009 | Anderson et al. |
7579381 | August 25, 2009 | Dove |
7585321 | September 8, 2009 | Cribier |
7618446 | November 17, 2009 | Andersen et al. |
7621948 | November 24, 2009 | Herrmann et al. |
7655034 | February 2, 2010 | Mitchell et al. |
7785366 | August 31, 2010 | Maurer et al. |
7887580 | February 15, 2011 | Randall et al. |
7959672 | June 14, 2011 | Salahieh et al. |
7993394 | August 9, 2011 | Hariton et al. |
8007992 | August 30, 2011 | Tian et al. |
8029556 | October 4, 2011 | Rowe |
8105375 | January 31, 2012 | Navia et al. |
8167932 | May 1, 2012 | Bourang et al. |
8323335 | December 4, 2012 | Rowe et al. |
8348963 | January 8, 2013 | Wilson |
8398704 | March 19, 2013 | Straubinger et al. |
8398708 | March 19, 2013 | Meiri et al. |
8449606 | May 28, 2013 | Eliasen et al. |
8657872 | February 25, 2014 | Seguin |
8747463 | June 10, 2014 | Fogarty et al. |
9095434 | August 4, 2015 | Rowe |
20010021872 | September 13, 2001 | Bailey et al. |
20020032481 | March 14, 2002 | Gabbay |
20020173842 | November 21, 2002 | Buchanan |
20030050694 | March 13, 2003 | Yang et al. |
20030074628 | April 17, 2003 | Lee |
20030100939 | May 29, 2003 | Yodfat et al. |
20030158597 | August 21, 2003 | Quiachon et al. |
20030212454 | November 13, 2003 | Scott et al. |
20040039436 | February 26, 2004 | Spenser et al. |
20040133263 | July 8, 2004 | Dusbabek et al. |
20040186563 | September 23, 2004 | Lobbi |
20040186565 | September 23, 2004 | Schreck |
20040260389 | December 23, 2004 | Case et al. |
20050096736 | May 5, 2005 | Osse et al. |
20050137691 | June 23, 2005 | Salahieh et al. |
20050149160 | July 7, 2005 | McFerran |
20050203614 | September 15, 2005 | Forster et al. |
20050203617 | September 15, 2005 | Forster et al. |
20050234546 | October 20, 2005 | Nugent et al. |
20050288766 | December 29, 2005 | Plain et al. |
20060025857 | February 2, 2006 | Bergheim et al. |
20060058872 | March 16, 2006 | Salahieh et al. |
20060142837 | June 29, 2006 | Haverkost et al. |
20060149350 | July 6, 2006 | Patel et al. |
20060229719 | October 12, 2006 | Marquez et al. |
20060259135 | November 16, 2006 | Navia et al. |
20060259137 | November 16, 2006 | Artof et al. |
20070005131 | January 4, 2007 | Taylor |
20070010877 | January 11, 2007 | Salahieh et al. |
20070027534 | February 1, 2007 | Bergheim et al. |
20070088431 | April 19, 2007 | Bourang et al. |
20070112422 | May 17, 2007 | Dehdashtian |
20070156224 | July 5, 2007 | Cioanta et al. |
20070203503 | August 30, 2007 | Salahieh et al. |
20070203575 | August 30, 2007 | Forster et al. |
20070260305 | November 8, 2007 | Drews et al. |
20070265700 | November 15, 2007 | Eliasen et al. |
20070270943 | November 22, 2007 | Solem et al. |
20080065011 | March 13, 2008 | Marchand et al. |
20080114442 | May 15, 2008 | Mitchell et al. |
20080125853 | May 29, 2008 | Bailey et al. |
20080154355 | June 26, 2008 | Benichou et al. |
20080161911 | July 3, 2008 | Revuelta et al. |
20080294230 | November 27, 2008 | Parker |
20090157175 | June 18, 2009 | Benichou |
20090164005 | June 25, 2009 | Dove et al. |
20090171456 | July 2, 2009 | Kveen et al. |
20090276040 | November 5, 2009 | Rowe et al. |
20090281619 | November 12, 2009 | Le et al. |
20090287299 | November 19, 2009 | Tabor et al. |
20090319037 | December 24, 2009 | Rowe et al. |
20100049313 | February 25, 2010 | Alon et al. |
20100198347 | August 5, 2010 | Zakay et al. |
20100204781 | August 12, 2010 | Alkhatib |
20100262233 | October 14, 2010 | He |
20110015729 | January 20, 2011 | Jimenez et al. |
20110098802 | April 28, 2011 | Braido et al. |
20110218620 | September 8, 2011 | Meiri |
20110264206 | October 27, 2011 | Tabor |
20120022633 | January 26, 2012 | Olson et al. |
20120123529 | May 17, 2012 | Levi et al. |
20130023985 | January 24, 2013 | Khairkhahan et al. |
20130317598 | November 28, 2013 | Rowe et al. |
20150282931 | October 8, 2015 | Brunnett et al. |
19546692 | June 1997 | DE |
19857887 | July 2000 | DE |
19907646 | August 2000 | DE |
10049812 | April 2002 | DE |
10049813 | April 2002 | DE |
10049814 | April 2002 | DE |
10049815 | April 2002 | DE |
202007005491 | June 2007 | DE |
0103546 | March 1984 | EP |
0144167 | June 1985 | EP |
0597967 | December 1994 | EP |
0592410 | October 1995 | EP |
0850607 | July 1998 | EP |
1057460 | December 2000 | EP |
1088529 | April 2001 | EP |
1570809 | September 2005 | EP |
1796597 | June 2007 | EP |
2788217 | July 2000 | FR |
2815844 | May 2002 | FR |
2056023 | March 1981 | GB |
1271508 | November 1986 | SU |
1991017720 | November 1991 | WO |
92/17118 | October 1992 | WO |
1993001768 | February 1993 | WO |
9640008 | December 1996 | WO |
97/24080 | July 1997 | WO |
1998029057 | July 1998 | WO |
9930646 | June 1999 | WO |
99/33414 | July 1999 | WO |
1999040964 | August 1999 | WO |
1999047075 | September 1999 | WO |
00/18333 | April 2000 | WO |
00/41652 | July 2000 | WO |
00/42950 | July 2000 | WO |
00/47139 | August 2000 | WO |
01/28459 | April 2001 | WO |
01/35878 | May 2001 | WO |
01/49213 | July 2001 | WO |
01/54624 | August 2001 | WO |
01/54625 | August 2001 | WO |
01/62189 | August 2001 | WO |
01/64137 | September 2001 | WO |
01/76510 | October 2001 | WO |
02/22054 | March 2002 | WO |
02/36048 | May 2002 | WO |
02/41789 | May 2002 | WO |
02/43620 | June 2002 | WO |
02/47575 | June 2002 | WO |
02/49540 | June 2002 | WO |
03/047468 | June 2003 | WO |
2005034812 | April 2005 | WO |
05/087140 | September 2005 | WO |
2005084595 | September 2005 | WO |
2005102015 | November 2005 | WO |
06/014233 | February 2006 | WO |
06/034008 | March 2006 | WO |
2006108090 | October 2006 | WO |
2006111391 | October 2006 | WO |
2006113906 | October 2006 | WO |
2006/138173 | December 2006 | WO |
2007047488 | April 2007 | WO |
2007067942 | June 2007 | WO |
2007097983 | August 2007 | WO |
08/005405 | January 2008 | WO |
08/035337 | March 2008 | WO |
2008029296 | March 2008 | WO |
08/091515 | July 2008 | WO |
08/147964 | December 2008 | WO |
08/150529 | December 2008 | WO |
09/033469 | March 2009 | WO |
2009116041 | September 2009 | WO |
2010112076 | October 2010 | WO |
2013037519 | March 2013 | WO |
2013114214 | August 2013 | WO |
2015023579 | February 2015 | WO |
2015023862 | February 2015 | WO |
- Al-Khaja et al., “Eleven Years' Experience with Carpentier-Edwards Biological Valves in Relation to Survival and Complications”, European Journal of Cardio-thoracic Surgery 3: pp. 305-311, 1989.
- Almagor et al., “Balloon Expandable Stent Implantation in Stenotic Right Heart Valved Conduits”, Journal of the American College of Cardiology, vol. 16, No. 6, pp. 1310-1314, Nov. 15, 1990.
- Al Zaibag et al., “Percutaneous Balloon Valvotomy in Tricuspid Stenosis”, British Heart Journal, vol. 57, No. 1, Jan. 1987.
- Andersen et al., “Transluminal Implantation of Artificial Heart Valves. Description of a New Expandable Aortic Valve and Initial Results with Implantation by Catheter Technique in Closed Chest Pigs”, European Heart Journal 13, pp. 704-708, 1992.
- Henning Rud Andersen, “History of Percutaneous Aortic Valve Prosthesis”, Herz 34, Urban and Vogel, pp. 343-346, 2009.
- Benchimol et al., “Simultaneous Left Ventricular Echocardiography and Aortic Blood Velocity During Rapid Right Ventricular Pacing in Man”, The American Journal of the Medical Sciences, vol. 273, No. 1, pp. 55-62, 1977.
- Dake et al., “Transluminal Placement of Endovascular Stent-Grafts for the Treatment of Descending Thoracic Aortic Aneurysms”, The New England Journal of Medicine, vol. 331, No. 26, pp. 1729-1734, Dec. 29, 1994.
- Dotter et al., “Transluminal Treatment of Arteriosclerotic Obstruction: Description of a New Technic and a Preliminary Report of Its Application”, Circulation, vol. XXX, pp. 654-670, 1964.
- Gina Kolata, “Device that Opens Clogged Arteries Gets a Failing Grade in a New Study”, The New York Times, http://www.nytimes.com/1991/01/03/health/device-that-opens-clogged-arteries-gets-a-faili . . . , pp. 1-2, wrriten Jan. 3, 199, web page access Jul. 29, 2009.
- Inoue et al., “Clinical Application of Transvenous Mitral Commissurotomy by a New Balloon Catheter”, The Journal of Thoracic and Cardiovascular Surgery, vol. 87, No. 3, pp. 394-402, 1984.
- Lawrence, Jr., et al., “Percutaneous Endovascular Graft: Experimental Evaluation”, Cardiovascular Radiology 163, pp. 357-360, May 1987.
- Pavcnik et al., “Development and Initial Experimental Evaluation of a Prosthetic Aortic Valve for a Transcatheter Placement: Work in Progress”, Cardiovascular Radiology; 183, pp. 151-154, Apr. 1992.
- Porstmann et al., “Der Verschluß des Ductus Arteriosus Persistens Ohne Thorakotomie”, Thoraxchirurgie Vaskuläre Chirurgie, Band 15, Heft 2, Stuttgart, im Apr. 1967, pp. 199-203.
- Rashkind et al., “Creation of an Atrial Septal Defect Without Thoracotomy: A Pallative Approach to Complete Transposition of the Great Arteries”, The Journal of the American Medical Association, vol. 196, No. 11, pp. 173-174, Jun. 13, 1956.
- Rashkind et al., “Historical Aspects of Interventional Cardiology: Past, Present, and Future”, Texas Heart Institute Journal, Interventional Cardiology, pp. 363-367.
- Rösch et al., “The Birth, Early Years, and Future of Interventional Radiology”, JVIR, vol. 14, No. 7, pp. 841-853, Jul. 2003.
- D.N. Ross, “Aortic Valve Surgery”, Surgery of the Aortic Valves, Guy's Hospital, London, pp. 192-197.
- Sabbah et al., “Mechanical Factors in the Degeneration of Porcine Bioprosthetic Valves: An Overview”, Journal of Cardiac Surgery, vol. 4, No. 4, pp. 302-309, Dec. 1989.
- Selby et al., “Experience with New Retrieval Forceps for Foreign Body Removal in the Vascular, Urinary, and Biliary Systems”, Radiology: 176. pp. 535-538, 1990.
- Serruys et al., “Stenting of Coronary Arteries. Are we the Sorcerer's Apprentice?”, European Heart Journal, 10, 774-782, pp. 37-45, 1989.
- Ulrich Sigwart, “An Overview of Intravascular Stents: Old and New”, Textbook of Interventional Cardiology, Secon Edition, pp. 803-815, 1990.
- Uchida et al., “Modifications of Gianturco Expandable Wire Stents”, Technical Note, American Roentgen Ray Society, pp. 1185-1187, May 1988.
- Philip Urban, MD, “Coronary Artery Stenting”, Editions Medecine et Hygiene, Geneve, pp. 1-47, 1991.
- Watt et al., “Intravenous Adenosine in the Treatment of Supraventricular Tachycardia: A Dose-Ranging Study and Interaction with Dipyridamole”, Br. J. Clin. Pharmac. 21, pp. 227-230, 1986.
- David J. Wheatley, “Valve Prosthesis”, Rob & Smith's Operative Surgery, pp. 415-424, 1986.
Type: Grant
Filed: Apr 7, 2017
Date of Patent: Dec 17, 2019
Patent Publication Number: 20170209265
Assignee: Edwards Lifesciences Corporation (Irvine, CA)
Inventors: Emil Karapetian (Huntington Beach, CA), Maria Charles Vija Stanislaus (Irvine, CA), Gregory Bak-Boychuk (San Clemente, CA), Christopher J. Olson (Aliso Viejo, CA), Cristobal R. Hernandez (Santa Ana, CA), William C. Brunnett (Mission Viejo, CA), Netanel Benichou (Hof HaCarmel), Lauren R. Freschauf (Rancho Santa Margarita, CA), Alexander J. Siegel (Costa Mesa, CA)
Primary Examiner: Katherine M Shi
Application Number: 15/482,555
International Classification: A61F 2/24 (20060101); A61F 2/88 (20060101); A61F 2/07 (20130101); A61F 2/82 (20130101); A61F 2/91 (20130101); A61F 2/958 (20130101);